Liver Disease

The human liver metabolises everything that enters the body. The main cell type in the liver responsible for this diverse function is the hepatocyte. The goal of this research is to engineer and manufacture the large amounts of hepatocytes required for the treatment of human liver disease. The hepatocyte technology developed in Edinburgh is robust, scalable and ready to move toward the clinic.

The team is interested in developing its technology as an extra-corporeal device, a strategy which has been shown clinically to support human liver function. While bio-artificial liver devices have been used successfully in the past, their widespread acceptance was limited due to the incorporation of animal products. Its future interest is therefore to generate the quantity of hepatocytes required to ‘fuel’ a bio-artificial liver device. The humanised bio-artificial liver will then be evaluated in the correct clinical context to determine its value in treating human liver disease. The research has three aims:

  • Scale up of existing hepatocyte manufacture under conditions required for clinical grade manufacture.  
  • Develop stem cell derived bio-artificial liver devices and validate those in appropriate pre-clinical models.
  • To generate the scientific evidence required to fund and begin human clinical trials.


Quick Donate



See how else UKSCF is helping stem cell research.

Read More


Your donations and fundraising help to advance the most promising research projects that have the greatest potential to deliver patient benefits.

Read more